At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Partially Blinded Randomized Clinical Trial to Study the Immunogenicity and Safety of Intradermal Administration of ZOSTAVAX™ (V211)
In Brief
A Phase 1 clinical trial evaluating ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous, ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous, and 4 other interventions for Herpes Zoster. Completed, enrolled 223 participants.
Detailed Summary
This study will compare the safety and immunogenicity of ZOSTAVAX™ (V211) administered both intradermally and subcutaneously at various doses.
Study Details
Timeline
Interventions
One 0.65 mL injection subcutaneously on Day 1
One approximately 0.22 mL injection subcutaneously on Day 1
Two intradermal injections of approximately 0.15 mL each on Day 1
One intradermal injection of approximately 0.1 mL on Day 1
Two intradermal placebo injections of approximately 0.15 mL each on Day 1
One intradermal placebo injection of approximately 0.1 mL on Day 1